R&D channel feed

The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

6 years ago

Roche's SMA chal­lenge to Bio­gen's Spin­raza fran­chise looms larg­er with piv­otal win

6 years ago

Roche steers Gazy­va in­to a new PhI­II pro­gram af­ter com­bo shows promise in lu­pus nephri­tis study

6 years ago

Aslan's lat­est can­cer fo­cus al­so flops, leav­ing just two ma­jor pro­grams for the trou­bled biotech

6 years ago

With key test still loom­ing, Cel­gene and Ac­celeron nab FDA okay for be­ta-tha­lassemia med

6 years ago

As­traZeneca, Fi­bro­Gen flag ap­peal­ing pooled safe­ty da­ta on roxa for key seg­ment of the CKD mar­ket

6 years ago

Anap­tys­Bio gives in­vestors a rash as its big bet on eczema fails, sink­ing stock

6 years ago

Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

6 years ago
Pharma

Eye­ing sec­ond Japan­ese ap­proval, Dai­ichi and Ex­elix­is an­nounce pos­i­tive piv­otal for kid­ney drug

6 years ago
Pharma

Scynex­is' lead drug scores in vagi­nal yeast in­fec­tion tri­al

6 years ago

De­clar­ing topline PhI­II win, Take­da re­vives block­buster hopes for its trou­bled mul­ti­ple myelo­ma drug

6 years ago

Ear­ly da­ta on Takeda's dengue vac­cine is promis­ing, but wait for the full dataset

6 years ago
Pharma

Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

6 years ago

Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build the team

6 years ago
Startups

Ear­ly da­ta on NextCure's im­muno-on­col­o­gy drug in lung can­cer pa­tients de­lights in­vestors

6 years ago

Tardy mar­ket­ing ap­pli­ca­tion fil­ing, tri­al fail­ure trou­ble Su­per­nus in­vestors

6 years ago

On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

6 years ago
Pharma

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

6 years ago
People

Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

6 years ago
Deals

It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

6 years ago

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

6 years ago

FDA to Aveo: That's still a 'no' on ti­vo. Aveo: We'll be back.

6 years ago

As­traZeneca wins ku­dos for pipeline turn­around in a new rank­ing of the top 10 R&D play­ers in the bio­phar­ma world

6 years ago
Pharma

Sanofi shows off pos­i­tive PhI­II tri­al re­sults for Tou­jeo, open­ing the door to a new group of di­a­betes pa­tients

6 years ago
First page Previous page 224225226227228229230 Next page Last page
A service from the Financial Times